Literature DB >> 17993339

Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update.

M Craig Hall1, Sam S Chang, Guido Dalbagni, Raj Som Pruthi, John Derek Seigne, Eila Curlee Skinner, J Stuart Wolf, Paul F Schellhammer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17993339     DOI： 10.1016/j.juro.2007.09.003

Source DB:  PubMed          Journal:  J Urol        ISSN： 0022-5347            Impact factor:   7.450


× No keyword cloud information.
  236 in total

1.  Canadian guidelines for treatment of non-muscle invasive bladder cancer: a focus on intravesical therapy.

Authors:  Wassim Kassouf; Ashish M Kamat; Alexander Zlotta; Bernard H Bochner; Ronald Moore; Alan So; Jonathan Izawa; Ricardo A Rendon; Louis Lacombe; Armen G Aprikian
Journal:  Can Urol Assoc J       Date:  2010-06       Impact factor: 1.862

Review 2.  Long-term outcomes of intravesical therapy for non-muscle invasive bladder cancer.

Authors:  Alon Z Weizer; Christopher Tallman; Jeffrey S Montgomery
Journal:  World J Urol       Date:  2010-11-28       Impact factor: 4.226

Review 3.  Management of carcinoma in situ of the bladder: best practice and recent developments.

Authors:  Dominic H Tang; Sam S Chang
Journal:  Ther Adv Urol       Date:  2015-12

4.  CUA guidelines on the management of non-muscle invasive bladder cancer.

Authors:  Wassim Kassouf; Samer L Traboulsi; Girish S Kulkarni; Rodney H Breau; Alexandre Zlotta; Andrew Fairey; Alan So; Louis Lacombe; Ricardo Rendon; Armen G Aprikian; D Robert Siemens; Jonathan I Izawa; Peter Black
Journal:  Can Urol Assoc J       Date:  2015-10-13       Impact factor: 1.862

5.  Association Between Number of Endoscopic Resections and Utilization of Bacillus Calmette-Guérin Therapy for Patients With High-Grade, Non-Muscle-Invasive Bladder Cancer.

Authors:  Andrew T Lenis; Nicholas M Donin; Mark S Litwin; Christopher S Saigal; Julie Lai; Jan M Hanley; Badrinath R Konety; Karim Chamie
Journal:  Clin Genitourin Cancer       Date:  2016-06-25       Impact factor: 2.872

Review 6.  Defining and treating the spectrum of intermediate risk nonmuscle invasive bladder cancer.

Authors:  Ashish M Kamat; J Alfred Witjes; Maurizio Brausi; Mark Soloway; Donald Lamm; Raj Persad; Roger Buckley; Andreas Böhle; Marc Colombel; Joan Palou
Journal:  J Urol       Date:  2014-03-25       Impact factor: 7.450

7.  Bladder perforation after immediate postoperative intravesical instillation of mitomycin C.

Authors:  Darwin Lim; Jonathan I Izawa; Paul Middlebrook; Joseph L Chin
Journal:  Can Urol Assoc J       Date:  2010-02       Impact factor: 1.862

8.  Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with non-muscle invasive bladder cancer? An update and cumulative meta-analysis.

Authors:  Jiangang Pan; Mo Liu; Xing Zhou
Journal:  Front Med       Date:  2014-05-08       Impact factor: 4.592

9.  Efficacy and safety of pirarubicin combined with hyaluronic acid for non-muscle invasive bladder cancer after transurethral resection: a prospective, randomized study.

Authors:  Weiping Huang; Feng Wang; Cunzao Wu; Weilie Hu
Journal:  Int Urol Nephrol       Date:  2015-03-12       Impact factor: 2.370

10.  Perioperative Intravesical Chemotherapy for Patients WithNon-Muscle-invasive Bladder Cancer: Understanding the Extent of and Sources of Variation in Guideline-recommended Use.

Authors:  Devon K Check; David S Aaronson; Matthew E Nielsen; Valerie S Lee; Isaac J Ergas; Janise M Roh; Lawrence H Kushi; Li Tang; Marilyn L Kwan
Journal:  Urology       Date:  2018-10-23       Impact factor: 2.649
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.